EGFR and neoplasm: As shown in Figures 7A,B, CRM197 treatment inhibited tumor growth; and Western blotting showed CRM197 inhibited the expression of p-EGFR, p-ERK, HIF-1α, and VEGF in vivo (Figure 7C), consistent with our in vitro results.